Neni Nurainy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Neni Nurainy has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Acep Riza Wijayadikusumah
PT. Bio Farma, Bandung, Indonesia
3 shared publications - Eli Keshavarz-Moore
Department of Biochemical Engineering, Faculty of Engineering Sciences, University College London, London WC1E 6BT, UK
3 shared publications - Salomé de Sá Magalhães
Department of Biochemical Engineering, Faculty of Engineering Sciences, University College London, London WC1E 6BT, UK
3 shared publications - Almir Yamanie
Department of Biochemical Engineering, Faculty of Engineering Sciences, University College London, London WC1E 6BT, UK
2 shared publications Desvita Sari
Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
2 shared publicationsIva Puspitasari
Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
2 shared publications
Latest Publications
- Open Access
- 9 February 2026
- Published by MDPI AG in Fermentation
- Vol. 12 (2) , 97
Enhancing Sustainability and Productivity in Komagataella phaffii Fermentation: A Techno-Economic Comparison of Fed-Batch and Continuous Cultivation with Mixed Induction Strategies
The increasing demand for recombinant proteins has driven innovation in bioprocessing strategies using Komagataella phaffii as a host organism. Conventional fed-batch cultivation with pure methanol induction remains widely used but presents challenges including high methanol consumption, extended downtime, and elevated operational costs. This study evaluates alternative strategies combining mixed induction (methanol/sorbitol) with continuous cultivation to enhance productivity, sustainability, and improved economic outcome. Using KEX2 protease as a model industrial recombinant protein, we compared four cultivation modes: fed-batch with methanol (benchmark), fed-batch with mixed induction, continuous with methanol, and continuous with mixed induction. Cell growth, volumetric yield, and specific productivity were evaluated at 5L scale and then modelled to simulate industrial scales (40 L and 400 L). Results demonstrate that continuous cultivation with mixed induction significantly improves yield up to 9-fold compared to conventional fed-batch and reduces methanol usage and oxygen demand. Techno-economic simulations reveal that a 40 L continuous process can match or exceed the output of two 400 L fed-batch runs, while lowering capital and operating costs and minimizing environmental footprint. This integrated strategy offers a scalable, low-cost, and safer method for recombinant protein production, supporting compact and sustainable manufacturing solutions.
- 9 February 2026
- Published by MDPI AG in Fermentation
- Vol. 12 (2) , 97
Open AccessEnhancing Sustainability and Productivity in Komagataella phaffii Fermentation: A Techno-Economic Comparison of Fed-Batch and Continuous Cultivation with Mixed Induction Strategies
The increasing demand for recombinant proteins has driven innovation in bioprocessing strategies using Komagataella phaffii as a host organism. Conventional fed-batch cultivation with pure methanol induction remains widely used but presents challenges including high methanol consumption, extended downtime, and elevated operational costs. This study evaluates alternative strategies combining mixed induction (methanol/sorbitol) with continuous cultivation to enhance productivity, sustainability, and improved economic outcome. Using KEX2 protease as a model industrial recombinant protein, we compared four cultivation modes: fed-batch with methanol (benchmark), fed-batch with mixed induction, continuous with methanol, and continuous with mixed induction. Cell growth, volumetric yield, and specific productivity were evaluated at 5L scale and then modelled to simulate industrial scales (40 L and 400 L). Results demonstrate that continuous cultivation with mixed induction significantly improves yield up to 9-fold compared to conventional fed-batch and reduces methanol usage and oxygen demand. Techno-economic simulations reveal that a 40 L continuous process can match or exceed the output of two 400 L fed-batch runs, while lowering capital and operating costs and minimizing environmental footprint. This integrated strategy offers a scalable, low-cost, and safer method for recombinant protein production, supporting compact and sustainable manufacturing solutions.
- Open Access
- 16 January 2026
- Published by MDPI AG in Preprints.org
Enhancing Sustainability and Productivity in Komagataella phaffii Fermentation: A Techno-Economic Comparison of Fed-Batch and Continuous Cultivation with Mixed Induction Strategies
The increasing demand for recombinant proteins has driven innovation in bioprocessing strategies using Komagataella phaffii as a host organism. Conventional fed-batch cultivation with pure methanol induction remains widely used but presents challenges including high methanol consumption, extended downtime, and elevated operational costs. This study evaluates alternative strategies combining mixed induction (methanol/sorbitol) with continuous cultivation to enhance productivity, sustainability, and improved economic outcome. Using KEX2 protease as a model industrial recombinant protein, we compared four cultivation modes: fed-batch with methanol (benchmark), fed-batch with mixed induction, continuous with methanol, and continuous with mixed induction. Cell growth, volumetric yield, and specific productivity were evaluated at 5L scale and then modelled to simulate industrial scales (40 L and 400 L). Results demonstrate that continuous cultivation with mixed induction significantly improves yield up to 9-fold compared to conventional fed-batch and reduces methanol usage and oxygen demand. Techno-economic simulations reveal that a 40 L continuous process can match or exceed the output of two 400 L fed-batch runs, while lowering capital and operating costs and minimising environmental footprint. This integrated strategy offers a scalable, cost-effective, and safer alternative for recombinant protein production, supporting the development of compact and sustainable manufacturing platform.
- 16 January 2026
- Published by MDPI AG in Preprints.org
Open AccessEnhancing Sustainability and Productivity in Komagataella phaffii Fermentation: A Techno-Economic Comparison of Fed-Batch and Continuous Cultivation with Mixed Induction Strategies
The increasing demand for recombinant proteins has driven innovation in bioprocessing strategies using Komagataella phaffii as a host organism. Conventional fed-batch cultivation with pure methanol induction remains widely used but presents challenges including high methanol consumption, extended downtime, and elevated operational costs. This study evaluates alternative strategies combining mixed induction (methanol/sorbitol) with continuous cultivation to enhance productivity, sustainability, and improved economic outcome. Using KEX2 protease as a model industrial recombinant protein, we compared four cultivation modes: fed-batch with methanol (benchmark), fed-batch with mixed induction, continuous with methanol, and continuous with mixed induction. Cell growth, volumetric yield, and specific productivity were evaluated at 5L scale and then modelled to simulate industrial scales (40 L and 400 L). Results demonstrate that continuous cultivation with mixed induction significantly improves yield up to 9-fold compared to conventional fed-batch and reduces methanol usage and oxygen demand. Techno-economic simulations reveal that a 40 L continuous process can match or exceed the output of two 400 L fed-batch runs, while lowering capital and operating costs and minimising environmental footprint. This integrated strategy offers a scalable, cost-effective, and safer alternative for recombinant protein production, supporting the development of compact and sustainable manufacturing platform.
- Open Access
- 5 September 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (9) , 956
Defining a Simplified Process in Yeast for Production of Enveloped VLP Dengue Vaccine
Dengue is a rapidly spreading mosquito-borne viral infection, with increasing reports of outbreaks globally. According to the World Health Organization (WHO), by 30 April 2024, over 7.6 million dengue cases were reported, including 3.4 million confirmed cases, more than 16,000 severe cases, and over 3000 deaths. As dengue remains endemic in many regions, there is a critical need for the development of new vaccines and manufacturing processes that are efficient, cost-effective, and capable of meeting growing demand. In this study, we explore an alternative process development pathway for the future manufacturing of a dengue vaccine, utilizing Komagataella phaffii (Pichia pastoris) as the host organism, one of the most promising candidates for the expression of heterologous proteins in vaccine development. It combines the speed and ease of highly efficient prokaryotic platforms with some key capabilities of mammalian systems, making it ideal for scalable and cost-effective production. The key outcomes of our research include (i) demonstrating the versatility of the Komagataella phaffii platform in the production of dengue viral-like particles (VLPs); (ii) optimizing the culture process using Design of Experiments (DoE) approaches in small-scale bioreactors; (iii) developing a novel purification platform for enveloped VLPs (eVLPs), and (iv) establishing alternative biophysical characterization methods for the dengue vaccine prototype. These findings provide a promising foundation for efficient and scalable production of dengue vaccines, addressing both technical and operational challenges in vaccine manufacturing.
- 5 September 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (9) , 956
Open AccessDefining a Simplified Process in Yeast for Production of Enveloped VLP Dengue Vaccine
Dengue is a rapidly spreading mosquito-borne viral infection, with increasing reports of outbreaks globally. According to the World Health Organization (WHO), by 30 April 2024, over 7.6 million dengue cases were reported, including 3.4 million confirmed cases, more than 16,000 severe cases, and over 3000 deaths. As dengue remains endemic in many regions, there is a critical need for the development of new vaccines and manufacturing processes that are efficient, cost-effective, and capable of meeting growing demand. In this study, we explore an alternative process development pathway for the future manufacturing of a dengue vaccine, utilizing Komagataella phaffii (Pichia pastoris) as the host organism, one of the most promising candidates for the expression of heterologous proteins in vaccine development. It combines the speed and ease of highly efficient prokaryotic platforms with some key capabilities of mammalian systems, making it ideal for scalable and cost-effective production. The key outcomes of our research include (i) demonstrating the versatility of the Komagataella phaffii platform in the production of dengue viral-like particles (VLPs); (ii) optimizing the culture process using Design of Experiments (DoE) approaches in small-scale bioreactors; (iii) developing a novel purification platform for enveloped VLPs (eVLPs), and (iv) establishing alternative biophysical characterization methods for the dengue vaccine prototype. These findings provide a promising foundation for efficient and scalable production of dengue vaccines, addressing both technical and operational challenges in vaccine manufacturing.
- Open Access
Study of the immunogenicity, efficacy and safety of recombinant RBD SARS-CoV-2 vaccine with CpG adjuvant in rodent, non-rodent and Maccaca fascicularis using Indonesian Strain Virus
SARS-CoV-2 is the leading cause of the COVID-19 pandemic that causes acute respiratory syndrome, emerged in late 2019, and was declared a global pandemic on March 11 th , 2020. A safe and effective vaccine that prevents SARS-CoV-2 infection or minimize SARS-CoV-2 disease burden is needed. However, in 2021, Low- and middle-income countries (LMICs) face challenges regarding supply of COVID-19 vaccines. Indonesia, as a public sector vaccine manufacturing in developing countries was developed COVID-19 vaccine using a platform based on recombinant subunit proteins, a Receptor Binding Domain (RBD) of SARS-CoV-2 formulated with combination of Alhydrogel and CpG Oligodeoxynucleotides 1018 (CpG). In this study, we report the preclinical study including immunogenicity, toxicity and efficacy of vaccine in animal models. The vaccine immunogenicity tested in mice and non-human primates, the toxicity was done in rodents and non-rodents and challenged study and efficacy was done in non-human primates (NHPs) model. The animal model was vaccinated intramuscularly (IM). The serology result in mice and non-human primates showed significant antibody titers and neutralizing antibody responses compared to the RBD formulations adjuvanted with Alhydrogel only. Safety study in Wistar rats and New Zealand rabbits for single-dose (acute toxicity) and repeated-dose (sub-chronic toxicity) showed no abnormalities in the animal’s organs and behaviors and no deaths were reported in tested animals. Two doses of vaccination have been shown to protect NHPs against SARS-CoV-2 infection, as detected by drastic viral reduction from sample swab in nasal, anal, trachea and nasal wash in 7 days after virus challenged, also viral load measurement from lung and BAL tissue showed negative result, which gave better result than negative control and control vaccine group. No evidence of disease enhancement was observed. These results support clinical development of SARS-CoV-2 vaccine, and in 2022 this vaccine has been approved for emergency use in Indonesia.
Open AccessStudy of the immunogenicity, efficacy and safety of recombinant RBD SARS-CoV-2 vaccine with CpG adjuvant in rodent, non-rodent and Maccaca fascicularis using Indonesian Strain Virus
SARS-CoV-2 is the leading cause of the COVID-19 pandemic that causes acute respiratory syndrome, emerged in late 2019, and was declared a global pandemic on March 11 th , 2020. A safe and effective vaccine that prevents SARS-CoV-2 infection or minimize SARS-CoV-2 disease burden is needed. However, in 2021, Low- and middle-income countries (LMICs) face challenges regarding supply of COVID-19 vaccines. Indonesia, as a public sector vaccine manufacturing in developing countries was developed COVID-19 vaccine using a platform based on recombinant subunit proteins, a Receptor Binding Domain (RBD) of SARS-CoV-2 formulated with combination of Alhydrogel and CpG Oligodeoxynucleotides 1018 (CpG). In this study, we report the preclinical study including immunogenicity, toxicity and efficacy of vaccine in animal models. The vaccine immunogenicity tested in mice and non-human primates, the toxicity was done in rodents and non-rodents and challenged study and efficacy was done in non-human primates (NHPs) model. The animal model was vaccinated intramuscularly (IM). The serology result in mice and non-human primates showed significant antibody titers and neutralizing antibody responses compared to the RBD formulations adjuvanted with Alhydrogel only. Safety study in Wistar rats and New Zealand rabbits for single-dose (acute toxicity) and repeated-dose (sub-chronic toxicity) showed no abnormalities in the animal’s organs and behaviors and no deaths were reported in tested animals. Two doses of vaccination have been shown to protect NHPs against SARS-CoV-2 infection, as detected by drastic viral reduction from sample swab in nasal, anal, trachea and nasal wash in 7 days after virus challenged, also viral load measurement from lung and BAL tissue showed negative result, which gave better result than negative control and control vaccine group. No evidence of disease enhancement was observed. These results support clinical development of SARS-CoV-2 vaccine, and in 2022 this vaccine has been approved for emergency use in Indonesia.
- Open Access
Urinary high-risk HPV DNA detection to enhance cervical cancer screening in developing countries
Objectives: To increase cervical cancer screening capacity and participation, we evaluated the performance of the newly developed hrHPV ReadyMix qPCR Kit for detecting high-risk Human Papillomavirus (HPV) in urine samples while simultaneously genotyping HPV16, HPV18, and HPV52. Methods: 876 samples were used to assess the performance of hrHPV ReadyMix qPCR Kit in detecting high-risk HPV in standard cervical swab sample compared to the Roche cobas 6800 HPV. The high-risk HPV detection in urine was compared to the corresponding paired cervical swab. Results: The sensitivity of HPV detection in cervical swabs using hrHPV ReadyMix qPCR Kit reached 96.55% and the specificity reached 99.87%. Despite higher Ct values, urine samples demonstrated 80.88% sensitivity and 100.00% specificity compared to cervical swabs. Our method enables population-based high-risk HPV analysis with a 6.62% HPV prevalence from cervical swabs and 6.28% from urine samples. Furthermore, urine samples using the hrHPV ReadyMix qPCR Kit showed comparable HPV type distribution and the ability to genotype HPV16 and HPV18, to Roche the cobas 6800 HPV. Conclusions: Self-collected urine samples offer a 98.48% diagnostic accuracy for detecting high-risk HPV infection. This study highlights the hrHPV ReadyMix qPCR Kit's potential in enhancing cervical cancer screening, offering valuable insights for future interventions.
Open AccessUrinary high-risk HPV DNA detection to enhance cervical cancer screening in developing countries
Objectives: To increase cervical cancer screening capacity and participation, we evaluated the performance of the newly developed hrHPV ReadyMix qPCR Kit for detecting high-risk Human Papillomavirus (HPV) in urine samples while simultaneously genotyping HPV16, HPV18, and HPV52. Methods: 876 samples were used to assess the performance of hrHPV ReadyMix qPCR Kit in detecting high-risk HPV in standard cervical swab sample compared to the Roche cobas 6800 HPV. The high-risk HPV detection in urine was compared to the corresponding paired cervical swab. Results: The sensitivity of HPV detection in cervical swabs using hrHPV ReadyMix qPCR Kit reached 96.55% and the specificity reached 99.87%. Despite higher Ct values, urine samples demonstrated 80.88% sensitivity and 100.00% specificity compared to cervical swabs. Our method enables population-based high-risk HPV analysis with a 6.62% HPV prevalence from cervical swabs and 6.28% from urine samples. Furthermore, urine samples using the hrHPV ReadyMix qPCR Kit showed comparable HPV type distribution and the ability to genotype HPV16 and HPV18, to Roche the cobas 6800 HPV. Conclusions: Self-collected urine samples offer a 98.48% diagnostic accuracy for detecting high-risk HPV infection. This study highlights the hrHPV ReadyMix qPCR Kit's potential in enhancing cervical cancer screening, offering valuable insights for future interventions.
- Open Access
- 8 March 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
Self-collected gargle specimen as a patient-friendly sample collection method for COVID-19 diagnosis in a population context
Scaling up SARS-CoV-2 testing and tracing continues to be plagued with the limitation of the sample collection method, which requires trained healthcare workers to perform and causes discomfort to the patients. In response, we assessed the performance and user preference of gargle specimens for qRT-PCR-based detection of SARS-CoV-2 in Indonesia. Inpatients who had recently been diagnosed with COVID-19 and outpatients who were about to perform qRT-PCR testing were asked to provide nasopharyngeal and oropharyngeal (NPOP) swabs and self-collected gargle specimens. We demonstrated that self-collected gargle specimens can be an alternative specimen to detect SARS-CoV-2 and the viral RNA remained stable for 31 days at room temperature storage. The developed method was validated for use on multiple RNA extraction kits and commercially available COVID-19 RT-PCR kits. Our developed method achieved a sensitivity of 91.38% when compared to paired NPOP swab specimens (Ct < 35), with 97.10% of patients preferring the self-collected gargle method.
- 8 March 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
Open AccessSelf-collected gargle specimen as a patient-friendly sample collection method for COVID-19 diagnosis in a population context
Scaling up SARS-CoV-2 testing and tracing continues to be plagued with the limitation of the sample collection method, which requires trained healthcare workers to perform and causes discomfort to the patients. In response, we assessed the performance and user preference of gargle specimens for qRT-PCR-based detection of SARS-CoV-2 in Indonesia. Inpatients who had recently been diagnosed with COVID-19 and outpatients who were about to perform qRT-PCR testing were asked to provide nasopharyngeal and oropharyngeal (NPOP) swabs and self-collected gargle specimens. We demonstrated that self-collected gargle specimens can be an alternative specimen to detect SARS-CoV-2 and the viral RNA remained stable for 31 days at room temperature storage. The developed method was validated for use on multiple RNA extraction kits and commercially available COVID-19 RT-PCR kits. Our developed method achieved a sensitivity of 91.38% when compared to paired NPOP swab specimens (Ct < 35), with 97.10% of patients preferring the self-collected gargle method.
- Open Access
- 2 September 2021
- Published by Springer Nature in Research Square
Self-collected gargle specimen as a patient-friendly sample collection method for COVID-19 diagnosis in a population context
Scaling up SARS-CoV-2 testing and tracing continues to be plagued with the limitation of the sample collection method, which requires trained healthcare workers to perform and causes discomfort to the patients. In response, we assessed the performance and user preference of gargle specimens for qRT-PCR-based detection of SARS-CoV-2 in Indonesia. Inpatients who had recently been diagnosed with COVID-19 and outpatients who were about to perform qRT-PCR testing were asked to provide nasopharyngeal and oropharyngeal (NPOP) swabs and self-collected gargle specimens. We demonstrated that self-collected gargle specimens can be an alternative specimen to detect SARS-CoV-2 and the viral RNA remained stable for 31 days at room temperature storage. The developed method was validated for use on multiple RNA extraction kits and commercially available COVID-19 RT-PCR kits. Our developed method achieved a sensitivity of 91.38% when compared to paired NPOP swab specimens (Ct < 35), with 97.10% of patients preferring the self-collected gargle method.
- 2 September 2021
- Published by Springer Nature in Research Square
Open AccessSelf-collected gargle specimen as a patient-friendly sample collection method for COVID-19 diagnosis in a population context
Scaling up SARS-CoV-2 testing and tracing continues to be plagued with the limitation of the sample collection method, which requires trained healthcare workers to perform and causes discomfort to the patients. In response, we assessed the performance and user preference of gargle specimens for qRT-PCR-based detection of SARS-CoV-2 in Indonesia. Inpatients who had recently been diagnosed with COVID-19 and outpatients who were about to perform qRT-PCR testing were asked to provide nasopharyngeal and oropharyngeal (NPOP) swabs and self-collected gargle specimens. We demonstrated that self-collected gargle specimens can be an alternative specimen to detect SARS-CoV-2 and the viral RNA remained stable for 31 days at room temperature storage. The developed method was validated for use on multiple RNA extraction kits and commercially available COVID-19 RT-PCR kits. Our developed method achieved a sensitivity of 91.38% when compared to paired NPOP swab specimens (Ct < 35), with 97.10% of patients preferring the self-collected gargle method.